Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374751 · ClinicalTrials.gov registry record · Phase 1
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
A Phase 1 study of Cancer and Pain, sponsored by New York Presbyterian Brooklyn Methodist Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00374751 is a Phase 1 study of Cancer and Pain that has completed, run by New York Presbyterian Brooklyn Methodist Hospital. The registered enrollment target is 29 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00374751, a Phase 1 study of Cancer and Pain, has completed, sponsored by New York Presbyterian Brooklyn Methodist Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance. The investigators are studying the effects (good or bad) of adding samarium (a radioactive substance) to the cement that is injected into the induced cavity.
Conditions Studied
Interventions
- DRUG Samarium (153SM)
Study Locations (1)
New York
- New York Methodist Hospital - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374751
The ClinicalTrials.gov registry entry for NCT00374751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is New York Presbyterian Brooklyn Methodist Hospital, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Samarium (153SM) is the first listed.
NCT00374751 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00374751 about?
NCT00374751 is a clinical study titled "Effect of Samarium on the Relief of Pain Due to Vertebral Metastases". Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance. The investigators are studying the effects (good or bad) o...
What is the current status of trial NCT00374751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-05. Estimated completion is 2016-01.
What conditions does trial NCT00374751 study?
This clinical trial studies the following conditions: Cancer, Pain, Metastasis.
What interventions are being tested in trial NCT00374751?
The interventions under investigation include: Samarium (153SM) (DRUG).
Who is sponsoring clinical trial NCT00374751?
This trial is sponsored by New York Presbyterian Brooklyn Methodist Hospital, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00374751 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.